title: Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
authors.forename: D
authors.initials: D
authors.lastname: Söhngen
authors.forename: U
authors.initials: U
authors.lastname: Bauser
authors.forename: C
authors.initials: C
authors.lastname: Boogen
authors.forename: C
authors.initials: C
authors.lastname: Aul
authors.forename: T
authors.initials: T
authors.lastname: Frieling
authors.forename: U
authors.initials: U
authors.lastname: Germing
authors.forename: P
authors.initials: P
authors.lastname: Schneider
authors.forename: G
authors.initials: G
authors.lastname: Kobbe
authors.forename: A
authors.initials: A
authors.lastname: Heyll
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006493:Heparin / Q000627:therapeutic use; D006504:Hepatic Veno-Occlusive Disease / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D012008:Recurrence; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005340:Fibrinogen; D006493:Heparin; D010959:Tissue Plasminogen Activator